基本信息
职称 二级主任医师、教授
职务 福建省肿瘤医院院长，党委副书记
研究方向 肿瘤放射治疗临床与基础研究
电子邮件 bencc@sina.com
个人简介
陈传本，男，二级主任医师，教授，博士生导师，福建省肿瘤医院院长，党委副书记。担任中国临床肿瘤学会理事、中国抗癌协会常务理事、福建省抗癌协会会长、中国临床肿瘤学会放疗专家委员会常务委员、中国临床肿瘤学会鼻咽癌专家委员会副主委、福建医学会肿瘤放射治疗分会副主委、福建医师协会肿瘤放疗医师分会会长等职务。常年担任国自然及省自然课题项目评审及科技奖评奖工作。并作为主要完成人参与制定CSCO鼻咽癌临床实践指南。主要研究肿瘤放射治疗基础及临床研究。在肿瘤及放疗专业顶级期刊《JOURNAL OF CLINICAL ONCOLOGY》、《RADIOTHERAPY ANDONCOLOGY》等以第一/通讯作者发表学术论文100余篇。
主要科研项目
1、DNA-PKcs调节cGAS-STING通路增敏放射治疗联合免疫治疗在头颈部鳞癌的应用及机制研究，福建省科学技术厅项目，主持
2、新型肿瘤放疗增敏及疗效实时成像评估体系的构建及应用研究，国家自然科学基金委员会，主持
3、福建省肿瘤放射与免疫治疗临床医学研究中心，福建省科学技术厅项目，主持
4、肿瘤放疗科国家临床重点专科项目，福建省卫生健康委员会项目，主持
获奖经历
1、2018年，福建省抗癌协会科技进步奖二等奖
2、2019年，福建医学科技奖二等奖
3、2021年，福建省科学技术进步奖一等奖
近五年发表的主要论文
1.Xu Q, Wang J, Sun Y, Lin Y, Liu J, Zhuo Y, Huang Z, Huang S, Chen Y, Chen L,Ke M, Li L, Li Z, Pan J, Song Y, Liu R, Chen C. Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic CervicalCancer: A Multicenter, Single-Arm, Prospective Phase II Trial. J Clin Oncol.2022
2.Tang LL, Chen YP, Chen CB, Chen MY, Chen NY, Chen XZ, Du XJ, Fang WF, Feng M,Gao J, Han F, He X, Hu CS, Hu DS, Hu GY, Jiang H, Jiang W, Jin F, Lang JY, LiJG, Lin SJ, Liu X, Liu QF, Ma L, Mai HQ, Qin JY, Shen LF, Sun Y, Wang PG, WangRS, Wang RZ, Wang XS, Wang Y, Wu H, Xia YF, Xiao SW, Yang KY, Yi JL, Zhu XD, MaJ. The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for thediagnosis and treatment of nasopharyngeal carcinoma. Cancer Commun (Lond). 2021
3.Lin X, Wang F, Chen J, Liu J, Lin YB, Li L, Chen CB, Xu Q.NN6-methyladenosine modification of CENPK mRNA by ZC3H13 promotes cervical cancer stemness and chemoresistance. Mil Med Res. 2022
4.Fei Z, Xu T, Qiu X, Li M, Chen T, Li L, Huang C, Chen C. Significance of boost dose for T4 nasopharyngeal carcinoma with residual primary lesion afterintensity-modulated radiotherapy. J Cancer Res Clin Oncol. 2021
5.Chen Y, Zheng X, Lin J, Gao X, Xiong J, Liu J, Fei Z, Chen C. A high homologous recombination deficiency score is associated with poor survival and anon-inflamed tumor microenvironment in head and neck squamous cell carcinomapatients. Oral Oncol. 2022
6.Chen C, Xu T, Qiu X, Xie S, You Z, Hu Y, Zheng Y, Liang Z, Huang C, Chen T,Li L, Liu J, Fei Z. Selectively recommend <sup>18</sup>F-FDG PET/CT for patientswith de novo nasopharyngeal carcinoma in endemic areas. Radiat Oncol. 2021
7.Chen Y, Li Y, Guan Y, Huang Y, Lin J, Chen L, Li J, Chen G, Pan LK, Xia X,Xu N, Chang L, Guo Z, Pan J, Yi X, Chen C.Prevalence of PRKDC mutations andassociation with response to immune checkpoint inhibitors in solid tumors. Mol Oncol. 2020
8.Feng Y, Xu Y, Xu T, Hong H, Chen J, Qiu X, Ding J, Huang C, Li L, Liu J, FeiZ, Chen C. Recommendation for imaging follow-up strategy based on time-specificdisease failure for nasopharyngeal carcinoma. Head Neck. 2023
9.Fei Z, Xu T, Hong H, Xu Y, Chen J, Qiu X, Ding J, Huang C, Li L, Liu J, ChenC. PET/CT standardized uptake value and EGFR expression predicts treatmentfailure in nasopharyngeal carcinoma. Radiat Oncol. 2023
10.Xu T, Feng Y, Hong H, Xu Y, Chen J, Qiu X, Ding J, Huang C, Li L, Chen C,Fei Z. Biological target volume based on fluorine-18-fluorode-oxyglucosepositron emission tomography/computed tomography imaging: a spurious proposition? Radiat Oncol. 2023
11.Wu Q, Ding Q, Lin W, Weng Y, Feng S, Chen R, Chen C, Qiu S, Lin D. Profilingof Tumor Cell-Delivered Exosome by Surface Enhanced Raman Spectroscopy-BasedBiosensor for Evaluation of Nasopharyngeal Cancer Radioresistance. Adv HealthcMater. 2023
12.Chen Y, Chen G, Li J, Huang YY, Li Y, Lin J, Chen LZ, Lu JP, Wang YQ, WangCX, Pan LK, Xia XF, Yi X, Chen CB, Zheng XW, Guo ZQ, Pan JJ. Association ofTumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response toImmune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell LungCancer. JAMA Netw Open. 2019
13.Feng Y, Xu T, Xu Y, Wu Z, Hong H, Huang Y, Liao X, Fu X, Chen J, Qiu X, DingJ, Huang C, Li L, Chen C, Fei Z. Do all patients at the initial stage of nasopharyngeal carcinoma need bone metastasis screening? A retrospective study.Head Neck. 2023
